Full Breakdown
Johnson & Johnson Ordered to Pay $40 Million in Talc-Related Ovarian Cancer Case
12/13/2025, 11:58:55 PM
Jury Verdict and Implications
On December 12, 2025, a Los Angeles jury awarded $40 million to two women, Monica Kent and Deborah Schultz, who claimed that Johnson & Johnson's (J&J) talcum powder products caused their ovarian cancer. The jury awarded $18 million to Kent and $22 million to Schultz and her husband, concluding that J&J had long been aware of the dangers associated with its talc-based products but failed to adequately warn consumers. Both women testified that they used J&J's baby powder for over 40 years, undergoing extensive treatments for their cancer, including major surgeries and numerous rounds of chemotherapy.
Background of the Case
This trial is part of a broader legal battle involving over 67,000 plaintiffs who allege that J&J's talc products are linked to various cancers, including ovarian cancer and mesothelioma. J&J has consistently maintained that its products are safe, free from asbestos, and do not cause cancer. The company ceased selling talc-based baby powder in the U.S. in 2020, transitioning to a cornstarch alternative amid declining sales and increasing litigation.
Legal Context and Company Response
The recent verdict marks the first trial since J&J's attempts to resolve its litigation through bankruptcy were rejected by federal courts. J&J's vice president of litigation, Erik Haas, stated that the company plans to appeal the verdict, asserting that it has won 16 of the 17 ovarian cancer cases previously tried. J&J's defense argued that the plaintiffs' claims lack substantial scientific backing, emphasizing that no major health authority has identified talc as a risk factor for ovarian cancer.
Evidence Presented at Trial
During the trial, plaintiffs' attorneys presented internal documents and expert testimonies suggesting that J&J knew about the potential risks of talc as early as the 1960s. They accused the company of prioritizing profits over consumer safety, claiming it concealed information regarding asbestos contamination in its products. Conversely, J&J's attorneys contended that the evidence did not establish a direct link between talc and ovarian cancer, arguing that the plaintiffs' claims were based on litigation-driven theories rather than reliable science.
Broader Legal Landscape
The outcome of this case could have significant implications for J&J, as it is seen as a bellwether trial that may influence the direction of future litigation. Prior to this case, J&J had experienced a mixed record in talc trials, with some verdicts reaching as high as $4.69 billion. The majority of ongoing lawsuits focus on ovarian cancer claims, while those alleging mesothelioma comprise a smaller portion. Recently, J&J faced substantial verdicts in mesothelioma cases, including a $966 million judgment in October.
Official Statements & Responses
In response to the verdict, J&J reiterated its position on the safety of its products. Erik Haas stated, “We expect to prevail as we typically do with aberrant adverse verdicts.” Meanwhile, plaintiffs' attorney Daniel Robinson emphasized the loyalty of the women to J&J, stating, “The only thing they did was be loyal to Johnson & Johnson as a customer for only 50 years.”
What's Next
As J&J prepares to appeal the verdict, the company will also face ongoing scrutiny from investors and the public regarding its talc products. The legal landscape remains complex, with thousands of similar cases pending across the country, and the outcome of this trial may set a precedent for future litigation.
